Publications
Polypeptides synthesized by common bacteria in the human gut improve rodent metabolism
Nature Microbiology (2025)
Intestinal pH: a major driver of human gut microbiota composition and metabolism
Nature Reviews Gastroenterology & Hepatology (2025)
Advanced Microbiome Therapeutics Accelerate MASLD Recovery by Restoring Intestinal Microbiota Equilibrium and the Gut-Liver Axis in a Mouse Model
Journal of Agricultural and Food Chemistry (2025)
Advanced microbiome therapeutics for oral delivery of peptides and proteins: Advances, challenges, and opportunities
Advanced Drug Delivery Reviews (2025)
The effect of aldafermin expressing-Escherichia coli Nissle 1917 along with dietary change on visceral adipose tissue in MASLD mouse model
International Journal of Obesity (2025)
Modulating tumor immunity using advanced microbiome therapeutics producing an indole metabolite
EMBO Reports (2025)
Metagenome-guided culturomics for the targeted enrichment of gut microbes
Nature communications (2025)
Advanced microbiome therapeutics as a novel modality for oral delivery of peptides to manage metabolic diseases
Trends in Endocrinology & Metabolism (2024)
Enhancing intestinal absorption of a macromolecule through engineered probiotic yeast in the murine gastrointestinal tract
Trends in Biotechnology (2024)
Genetic heterogeneity of engineered Escherichia coli Nissle 1917 strains during scale-up simulation
Metabolic Engineering (2024)
AI is a viable alternative to high throughput screening: a 318-target study
Scientific Reports (2024)
Heterologous expression and antimicrobial potential of class II bacteriocins
Gut microbes (2024)
Candida expansion in the human gut is associated with an ecological signature that supports growth under dysbiotic conditions
Nature Communications(2023)
Changes in liver metabolic pathways demonstrate efficacy of the combined dietary and microbial therapeutic intervention in MASLD mouse model
Molecular Metabolism (2023)
Saccharomyces boulardii promoters for control of gene expression in vivo
Microbial Cell Factories (2023)
Programming Probiotics: Diet-Responsive Gene Expression and Colonization Control in Engineered S. boulardii
ACS Synthetic Biology (2023)
Cold Exposure and Oral Delivery of GLP-1R Agonists by an Engineered Probiotic Yeast Strain Have Antiobesity Effects in Mice
ACS Synthetic Biology (2023)
Engineered E. coli Nissle 1917 for delivery of bioactive IL-2 for cancer immunotherapy
Scientific Reports (2023)
Characterization of 8 bacterial biosensors for diagnostic and therapeutic applications
ACS synthetic biology (2023)
Identification of effective cell penetration peptides with minimal impact on gut commensals
Frontiers in Pharmacology (2023)
Biocontainment strategies for in vivo applications of Saccharomyces boulardii
Frontiers in Bioengineering and Biotechnology (2022)
Effects of broad-spectrum antibiotics on the probiotic yeast Saccharomyces boulardii colonisation in a mouse
Scientific Reports (2022)
Identification and Optimization of Novel Small-molecule Cas9 Inhibitors by Cell-based High-throughput Screening
Journal of medicinal chemistry (2022)
Challenging the hypothesis of bile acids de novo biosynthesis by marine bacteria
Microbiology and Biotechnology letters (2022)
Escherichia coli promoters with consistent expression throughout the murine gut
ACS Synthetic Biology (2021)
AcrIIA22 is a novel anti-CRISPR that impairs SpyCas9 activity by relieving DNA torsion of target plasmid
PLOS Biology (2021)
Bacterial resistance to CRISPR-Cas antimicrobials
Scientific Reports (2021)
Metabolic modeling predicts specific gut bacteria as key determinants for Candida albicans colonization levels
ISME (2020)
Antibiotics create a shift from mutualism to competition in human gut communities with a longer-lasting impact on fungi than bacteria
Microbiome 8 (1), 1-20
Predictable modulation of cancer treatment outcomes by the gut microbiota
Microbiome 8 (1), 1-14 (2020)
Discovery and characterization of Cas9 inhibitors disseminated across seven bacterial phyla
Cell host & microbe 25 (2), 233-241. e5 (2019)
* Ruben Vazquez Uribe as corresponding author
** First author publications of Ruben Vazquez Uribe
Patents
Ruben V. Uribe is the co-inventor of several issued patents and additional patent applications licensed to public and private companies.
- Altering microbial populations and modifying microbiota – US Patent no. 12226430B2
- Method for the modulation of cancer treatment based on analyzing the gut microbiome – WO Patent no. 2021176036
- Drug-delivering bacteria – WO Patent no. 2023175124
- Methods for treatment of non-alcoholic fatty liver diseases (nafld) using advanced microbiome therapeutics – WO Patent no. 2023208816, US Patent no. 18857837
- Inhibitors of crispr-cas associated activity – WO Patent no. 2019185751
- Single-vector type i vectors – US Patent no. 11851663B2
- Engineered bacteria secreting cytokines for use in cancer immunotherapy – WO Patent no. 2023161371
- A high-throughput platform to select for regulators of crispr-cas associated activity – WO Patent no. 2019185750
Ruben Vazquez-Uribe 